Relationships between tumor CD147 expression, tumor-infiltrating lymphocytes, and oncostatin M in hepatocellular carcinoma.
CD147
Hepatic fibrosis
Immunity
Immunohistochemistry
Liver cancer
Oncostatin M
Regulatory T cells
Tumor-immune microenvironment
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
05
07
2024
accepted:
29
09
2024
revised:
02
09
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
12
10
2024
Statut:
aheadofprint
Résumé
In hepatocellular carcinoma (HCC), CD147 expression contributes to tumor malignancy; however, its relationship with the tumor-immune microenvironment (TIME) remains unclear. This study aimed to elucidate the clinicopathological characteristics associated with CD147 expression in HCC and investigate its association with the TIME, specifically its association with tumor-infiltrating lymphocytes (TILs) and oncostatin M (OSM). Using 397 HCC specimens from patients undergoing curative-intent resection, we assessed CD147 expression in tumor cells and quantified OSM-positive cells and various TILs (CD8
Identifiants
pubmed: 39395054
doi: 10.1007/s00428-024-03939-w
pii: 10.1007/s00428-024-03939-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : JSPS KAKENHI
ID : JP22H02930
Organisme : JSPS KAKENHI
ID : JP23K18246
Organisme : JSPS KAKENHI
ID : JP23K14491
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F (2020) Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(335–349):e315. https://doi.org/10.1053/j.gastro.2020.02.068
doi: 10.1053/j.gastro.2020.02.068
Ding J, Wen Z (2021) Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 21:1157. https://doi.org/10.1186/s12885-021-08904-3
doi: 10.1186/s12885-021-08904-3
pubmed: 34715816
pmcid: 8555190
Landras A, Reger de Moura C, Jouenne F, Lebbe C, Menashi S, Mourah S (2019) CD147 Is a promising target of tumor progression and a prognostic biomarker. Cancers (Basel) 11:1803. https://doi.org/10.3390/cancers11111803
doi: 10.3390/cancers11111803
pubmed: 31744072
Huang D, Rao D, Jin Q, Lai M, Zhang J, Lai Z, Shen H, Zhong T (2023) Role of CD147 in the development and diagnosis of hepatocellular carcinoma. Front Immunol 14:1149931. https://doi.org/10.3389/fimmu.2023.1149931
doi: 10.3389/fimmu.2023.1149931
pubmed: 37090718
pmcid: 10115957
Nyalali AMK, Leonard AU, Xu Y, Li H, Zhou J, Zhang X, Rugambwa TK, Shi X, Li F (2023) CD147: an integral and potential molecule to abrogate hallmarks of cancer. Front Oncol 13:1238051. https://doi.org/10.3389/fonc.2023.1238051
doi: 10.3389/fonc.2023.1238051
pubmed: 38023152
pmcid: 10662318
Peng F, Li H, You Q, Li H, Wu D, Jiang C, Deng G, Li Y, Li Y, Wu Y (2017) CD147 as a novel prognostic biomarker for hepatocellular carcinoma: a meta-analysis. Biomed Res Int 2017:5019367. https://doi.org/10.1155/2017/5019367
doi: 10.1155/2017/5019367
pubmed: 28386553
pmcid: 5366185
Zhang Q, Zhou J, Ku XM, Chen XG, Zhang L, Xu J, Chen GS, Li Q, Qian F, Tian R, Wen N, Chen ZN (2007) Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev 16:196–202. https://doi.org/10.1097/01.cej.0000236245.40619.c3
doi: 10.1097/01.cej.0000236245.40619.c3
pubmed: 17415090
Zhu S, Li Y, Zhang Y, Wang X, Gong L, Han X, Yao L, Lan M, Zhang W (2015) Expression and clinical implications of HAb18G/CD147 in hepatocellular carcinoma. Hepatol Res 45:97–106. https://doi.org/10.1111/hepr.12320
doi: 10.1111/hepr.12320
pubmed: 24593119
Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55:434–439
pubmed: 7812975
Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN (2007) HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 5:605–614. https://doi.org/10.1158/1541-7786.MCR-06-0286
doi: 10.1158/1541-7786.MCR-06-0286
pubmed: 17579119
Ru NY, Wu J, Chen ZN, Bian H (2015) HAb18G/CD147 is involved in TGF-beta-induced epithelial-mesenchymal transition and hepatocellular carcinoma invasion. Cell Biol Int 39:44–51. https://doi.org/10.1002/cbin.10341
doi: 10.1002/cbin.10341
pubmed: 25044444
Levy MT, Trojanowska M, Reuben A (2000) Oncostatin M: a cytokine upregulated in human cirrhosis, increases collagen production by human hepatic stellate cells. J Hepatol 32:218–226. https://doi.org/10.1016/s0168-8278(00)80066-5
doi: 10.1016/s0168-8278(00)80066-5
pubmed: 10707861
Znoyko I, Sohara N, Spicer SS, Trojanowska M, Reuben A (2005) Expression of oncostatin M and its receptors in normal and cirrhotic human liver. J Hepatol 43:893–900. https://doi.org/10.1016/j.jhep.2005.04.020
doi: 10.1016/j.jhep.2005.04.020
pubmed: 16169119
Di Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S, Novo E, Alvaro M, Autelli R, Colombatto S, Bussolino F, Carucci P, Gaia S, Rosso C, Biasiolo A, Pontisso P, Bugianesi E, Albano E, Marra F, Parola M, Cannito S (2022) Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. J Pathol 257:82–95. https://doi.org/10.1002/path.5871
doi: 10.1002/path.5871
pubmed: 35064579
pmcid: 9315146
Shigematsu Y, Tanaka K, Amori G, Kanda H, Takahashi Y, Takazawa Y, Takeuchi K, Inamura K (2023) Potential involvement of oncostatin M in the immunosuppressive tumor-immune microenvironment in hepatocellular carcinoma with vessels encapsulating tumor clusters. Hepatol Res. https://doi.org/10.1111/hepr.13988
doi: 10.1111/hepr.13988
pubmed: 37950386
Chan AW, Kumada T, Toyoda H, Tada T, Chong CC, Mo FK, Yeo W, Johnson PJ, Lai PB, Chan AT, To KF, Chan SL (2016) Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol 31:1300–1306. https://doi.org/10.1111/jgh.13291
doi: 10.1111/jgh.13291
pubmed: 26751608
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388
doi: 10.3322/caac.21388
pubmed: 28094848
Torbenson M, Ng IOL, Park YN, Roncalli M, Sakamoto M (2019) Hepatocellular carcinoma. In: WHO classification of tumours editorial board, editor. Digestive system tumours. International Agency for Research on Cancer, Lyon
Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T (2021) Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10:181-223. https://doi.org/10.1159/000514174
Brunt EM, Tiniakos DG (2010) Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16:5286–5296. https://doi.org/10.3748/wjg.v16.i42.5286
doi: 10.3748/wjg.v16.i42.5286
pubmed: 21072891
pmcid: 2980677
Shigematsu Y, Amori G, Kanda H, Takahashi Y, Takazawa Y, Takeuchi K, Inamura K (2022) Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. Virchows Arch 481:253–263. https://doi.org/10.1007/s00428-022-03318-3
doi: 10.1007/s00428-022-03318-3
pubmed: 35459975
Shigematsu Y, Inamura K, Yamamoto N, Mise Y, Saiura A, Ishikawa Y, Takahashi S, Kanda H (2018) Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer 18:980. https://doi.org/10.1186/s12885-018-4902-8
doi: 10.1186/s12885-018-4902-8
pubmed: 30326864
pmcid: 6192098
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019
doi: 10.1038/nmeth.2019
pubmed: 22743772
Caligiuri A, Gitto S, Lori G, Marra F, Parola M, Cannito S, Gentilini A (2022) Oncostatin M: from intracellular signaling to therapeutic targets in liver cancer. Cancers (Basel) 14:4211. https://doi.org/10.3390/cancers14174211
doi: 10.3390/cancers14174211
pubmed: 36077744
Xu YJ, He HJ, Wu P, Li WB (2023) Expression patterns of cluster of differentiation 147 impact the prognosis of hepatocellular carcinoma. World J Gastrointest Oncol 15:1412–1423. https://doi.org/10.4251/wjgo.v15.i8.1412
doi: 10.4251/wjgo.v15.i8.1412
pubmed: 37663949
pmcid: 10473926
Guo F, Li H, Wang L, Song X, Wang J, Feng Q, Zong J (2022) Rs6757 in microRNA-3976 binding site of CD147 confers risk of hepatocellular carcinoma in South Chinese population. World J Surg Oncol 20:260. https://doi.org/10.1186/s12957-022-02724-w
doi: 10.1186/s12957-022-02724-w
pubmed: 35978360
pmcid: 9382786
Zhang JJ, Song CG, Dai JM, Zhang XQ, Lin P, Li L, Yang XM, Chen ZN (2021) Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway. Am J Transl Res 13:3967–3986
pubmed: 34149993
pmcid: 8205673
Pomlok K, Pata S, Kulaphisit M, Pangnuchar R, Wipasa J, Smith DR, Kasinrerk W, Lithanatudom P (2022) An IgM monoclonal antibody against domain 1 of CD147 induces non-canonical RIPK-independent necroptosis in a cell type specific manner in hepatocellular carcinoma cells. Biochim Biophys Acta Mol Cell Res 1869:119295. https://doi.org/10.1016/j.bbamcr.2022.119295
doi: 10.1016/j.bbamcr.2022.119295
pubmed: 35598753
Fukuchi K, Nanai K, Yuita H, Maru C, Tsukada J, Ishigami M, Nagai Y, Nakano Y, Yoshimura C, Yoneda K, Amano M, Nakamura K, Oda Y, Nishigohri H, Yamamoto S, Ohnishi-Totoki Y, Inaki K, Komori H, Nakano R, Kanari Y, Nishida A, Matsui Y, Funo S, Takahashi S, Ohtsuka T, Agatsuma T (2022) Novel antibody exerts antitumor effect through downregulation of CD147 and activation of multiple stress signals. J Oncol 2022:3552793. https://doi.org/10.1155/2022/3552793
doi: 10.1155/2022/3552793
pmcid: 9652086
Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D (2020) Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun 11:4810. https://doi.org/10.1038/s41467-020-18444-2
doi: 10.1038/s41467-020-18444-2
pmcid: 7511348
Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T, Ji L (2017) The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a systematic review and meta-analysis. Sci Rep 7:7525. https://doi.org/10.1038/s41598-017-08128-1
doi: 10.1038/s41598-017-08128-1
pubmed: 28790445
pmcid: 5548736
Giannelli G, Koudelkova P, Dituri F, Mikulits W (2016) Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol 65:798–808. https://doi.org/10.1016/j.jhep.2016.05.007
doi: 10.1016/j.jhep.2016.05.007
pubmed: 27212245
Junk DJ, Bryson BL, Smigiel JM, Parameswaran N, Bartel CA, Jackson MW (2017) Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene 36:4001–4013. https://doi.org/10.1038/onc.2017.33
doi: 10.1038/onc.2017.33
pubmed: 28288136
pmcid: 5509502
Smigiel JM, Parameswaran N, Jackson MW (2017) Potent EMT and CSC phenotypes are induced by oncostatin-M in pancreatic cancer. Mol Cancer Res 15:478–488. https://doi.org/10.1158/1541-7786.MCR-16-0337
doi: 10.1158/1541-7786.MCR-16-0337
pubmed: 28053127
pmcid: 5380554
Son HJ, Lee SH, Lee SY, Kim EK, Yang EJ, Kim JK, Seo HB, Park SH, Cho ML (2017) Oncostatin M suppresses activation of IL-17/Th17 via SOCS3 regulation in CD4+ T cells. J Immunol 198:1484–1491. https://doi.org/10.4049/jimmunol.1502314
doi: 10.4049/jimmunol.1502314
pubmed: 28093521
pmcid: 5292586
Calabro SR, Maczurek AE, Morgan AJ, Tu T, Wen VW, Yee C, Mridha A, Lee M, d’Avigdor W, Locarnini SA, McCaughan GW, Warner FJ, McLennan SV, Shackel NA (2014) Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS ONE 9:e90571. https://doi.org/10.1371/journal.pone.0090571
doi: 10.1371/journal.pone.0090571
pubmed: 25076423
pmcid: 4116334
Matsuda M, Tsurusaki S, Miyata N, Saijou E, Okochi H, Miyajima A, Tanaka M (2018) Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice. Hepatology 67:296–312. https://doi.org/10.1002/hep.29421
doi: 10.1002/hep.29421
pubmed: 28779552